Canopy Development Granted Licensing for Extraction Facility


With new regulations about to arrive for edible and vape items in October, Ontario-primarily based Canopy Development Corporation (TSX: WEED NYSE: CGC) just added a third extraction facility to the organization lineup. 

The existing KeyLeaf Life Sciences web page in Saskatoon is now officially licensed by Well being Canada and is on track to commence extracting hemp and cannabis biomass this coming fall. 

Canopy Development added the web page to the organization roster with the acquisition of KeyLeaf Life Sciences (formerly recognized as POS Bio-Science) back in June.

The facility was then retrofitted in the intervening months and will be capable of extracting five,000 kg per day for a range of CBD and THC items. Notably, extraction processes at the web page will be utilized for the extended-awaited cannabis infused beverage launch anticipated to arrive by the finish of the year.

Canopy Growth’s Chief Executive Officer Mark Zekulin – who stepped into the part right after Bruce Linton was ousted last month – had this to say about the newly authorized facility licensing: 

With this milestone, we are executing the vision of creating strategic investments currently to provide outcomes more than the extended term. This license will make sure we have the provide of extraction inputs for the healthcare, CBD, and recreational markets, specially the subsequent generation of worth-added, higher margin cannabis items right here in Canada.

Aside from gearing up to generate that new line of items such as vaporizer pods and edibles, Canopy Development not too long ago extended a U.S. distribution deal with Greenlane Holdings. That deal was handled by way of subsidiary Storz &amp Bickel and will see the new Volcano Hybrid vaporizer model hitting shelves across the United States. 

Bumping up extraction efforts and inking distribution bargains are two prongs of the company’s strategy to rising income in light of poor quarterly economic numbers. 

Canopy’s stock has gone by way of a series of peaks and valleys in current months, skyrocketing up to $56.89 a share just right after recreational legalization final year but then following the general cannabis market trend downward to a existing price tag of $25.19. 

In other organization news, earlier this month Canopy entered an agreement to obtain investigation organization Beckley Canopy Therapeutics, which will help the industrial side of healthcare subsidiary Spectrum Therapeutics. 


Latest posts